Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaCyte Biotech has announced to carry out pancreatic cancer clinical trial in the US.
Subscribe to our email newsletter
The trial, which will also include study sites in Europe and Australia, is designed to identify whether the company’s pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses ifosfamide chemotherapy) can satisfy a critical unmet medical need for pancreatic cancer patients.
After the successful trial, PharmaCyte intends to seek marketing approval for the treatment from drug regulatory authorities.
The company said the combination of Abraxane + gemcitabine is considered to be the gold standard to treat advanced pancreatic cancer in the US, in several countries across Europe and in Australia.
If patients fail to respond further to the Abraxane + gemcitabine combination, the following therapies will be only marginally effective.
The company’s treatment intends to fill the gap as part of a new consolidation therapy for pancreatic cancer patients.
PharmaCyte Biotech CEO Kenneth Waggoner said: "We believe that, by conducting our upcoming clinical trial in the United States, Europe and Australia, enrolling patients in the clinical trial will be much faster than previously planned and the overall timeline for the trial will be optimized.
"We selected TD2 to be the lead CRO because TD2 is setting the standard for new oncology drug approvals in the United States."
Apart from developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes.
Image: PharmaCyte Biotech will carry out pancreatic cancer clinical trial in the US with additional study sites in Europe and Australia. Photo: courtesy of dream designs/FreeDigitalPhotos.net.